Hi Sailinyaas, I agree that the BNC 210 readout will be in H2...

Hi Sailinyaas,

I agree that the BNC 210 readout will be in H2 2018 as per latest company presentation.

However, the readout timeframe is basically determined by when the recruitment phase ends.

If they have had better than expected enrollment in the trial, then the readout could yet come sooner than the market currently thinks.

The problem is that we do not know how enrollment is progressing.

The difficulty for the company in informing the market is that even if they were ahead of schedule, they probably don't want to simply presume that the quicker enrollment rate would continue until full enrollment has been completed.

The earliest we will have any idea on this is probably when they announce that they have completed enrollment - and there is no way anyone can know when that might occur.

Needless to say, that if patients on the trials are responding positively, then the doctors involved in recruitment would have increased confidence in enrolling patients.

Conversely, if the early "enrollees" were not responding well, then one would expect a slower rate of enrollment.

Its all a little arbitrary, but the end of enrollment will be an important lead indicator I suspect.

The company presentation indicates that each enrollee is treated for 12 weeks and then tested for response.

So its a three month lag between end of enrollment and collection of final data sets for analysis.

One would think that the top line readout would come no more than 4 weeks after the last enrollee has completed treatment - and possibly sooner if results are being input during the course of the trial.

In any event there are other catalysts to get the punters interested - so hang on for the ride of your life - BNO just might be one of 2018's great performers!

GLTA & DYOR